<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402180</url>
  </required_header>
  <id_info>
    <org_study_id>2010ESO_FU</org_study_id>
    <nct_id>NCT01402180</nct_id>
  </id_info>
  <brief_title>Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy</brief_title>
  <acronym>Nimotuzumab</acronym>
  <official_title>A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II tials to study whether it's benefit of adding Nimotuzumab to
      chemoradiation for patients with esophageal squamous cell carcinoma after radical
      esophagectomy who suffer with locoregional lymph nodes recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient population:

      Esophageal squamous cell carcinoma after radical esophagectomy, then recurrent with lymph
      nodes in bilateral supravascular fossa or upper mediastinum 6 months beyond esophagectomy.

      Scheme:

      Eligible recurrent patients with esophageal cancer will first be stratified by recurrent time
      after esophagectomy (within 2 years after esophagectomy, or beyond 2 years after
      esophagectomy), then randomized to 2 arms at 1:1 ratio.

      Arm A:

      Chemoradiation + weekly Nimotuzumab for 6 weeks concurrent with radiation.

      Arm B:

      Chemoradiation only.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <description>To evaluate if the addition of nimotuzumab to chemoradiation improves local control compared to chemoradiation only in patients with esophageal squamous cell carcinoma after radical esophagectomy who recurrent in regional lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <description>To evaluate if the addition of nimotuzumab to chemoradiation improves overall survival compared to chemoradiation only in patients with esophageal squamous cell carcinoma after radical esophagectomy who recurrent in regional lymph nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized in Arm B will receive chemoradiation only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤75

          2. ECOG performance status 0-2

          3. Histologically proven primary thoracic esophageal squamous cell carcinoma before

          4. Diagnosis of regional lymph nodes (biosupravascular fossa or upper mediastinum)
             recurrence after radical esophagectomy, based on pathological finding or imaging
             showing lymph nodes enlargement

          5. Period from esophagectomy to diagnosis of regional lymph nodes recurrence should be
             more than 6 months

          6. Without prior radiotherapy

          7. Weight loss no more than 10% in the past 6 months

          8. WBC≥ 4.0X109/L ,Absolute neutrophil count (ANC) ≥ 2.0X109/L

          9. Platelets ≥ 100X109/L

         10. Hemoglobin ≥ 90g/L(without blood transfusion)

         11. AST (SGOT)/ALT (SGPT) ≤ 2.5 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of
             normal

         12. Creatinine ≤ 1.5 x upper limit of normal

         13. Sign study-specific informed consent prior to study entry

        Exclusion Criteria:

          1. With recurrence or metastasis other than regional lymph nodes (biosupravascular fossa
             or upper mediastinum)

          2. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity,
             or cervix are all permissible).

          3. Severe, active comorbidity, defined as follows:

             3.1 Unstable angina and/or congestive heart failure requiring hospitalization within
             the last 3 months 3.2 Transmural myocardial infarction within the last 6 months 3.3
             Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration 3.4 Chronic obstructive pulmonary disease exacerbation or other
             respiratory illness requiring hospitalization or precluding study therapy at the time
             of registration 3.5 Acquired immune deficiency syndrome (AIDS) based upon current CDC
             definition; note, however, that HIV testing is not required for entry into this
             protocol. The need to exclude patients with AIDS from this protocol is necessary
             because the treatments involved in this protocol may be significantly
             immunosuppressive.

          4. Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception.

          5. Prior radiation therapy or prior target drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Long Fu, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu-Wei Cai, M.D., Ph.D.</last_name>
    <phone>8621-64175590</phone>
    <phone_ext>1504</phone_ext>
    <email>birdhome2000@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu-Wei Cai, M.D., Ph.D.</last_name>
      <phone>8621-64175590</phone>
      <phone_ext>1504</phone_ext>
      <email>birdhome2000@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiao-Long Fu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>July 25, 2011</last_update_submitted>
  <last_update_submitted_qc>July 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Xiao-Long Fu / Professor</name_title>
    <organization>Fudan University Cancer Center</organization>
  </responsible_party>
  <keyword>Esophageal squamous cell carcinoma</keyword>
  <keyword>lymph nodes recurrence</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>Nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

